ATE422494T1 - Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung - Google Patents

Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung

Info

Publication number
ATE422494T1
ATE422494T1 AT00978215T AT00978215T ATE422494T1 AT E422494 T1 ATE422494 T1 AT E422494T1 AT 00978215 T AT00978215 T AT 00978215T AT 00978215 T AT00978215 T AT 00978215T AT E422494 T1 ATE422494 T1 AT E422494T1
Authority
AT
Austria
Prior art keywords
pyridazines
inhibiting effect
substituted pyridines
angiogenesis inhibiting
angiogenesis
Prior art date
Application number
AT00978215T
Other languages
English (en)
Inventor
Jacques Dumas
Teddy JOE
Harold Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert Sibley
Ning Su
Stephen Boyer
Julie Dixon
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Application granted granted Critical
Publication of ATE422494T1 publication Critical patent/ATE422494T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AT00978215T 1999-09-28 2000-09-26 Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung ATE422494T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28

Publications (1)

Publication Number Publication Date
ATE422494T1 true ATE422494T1 (de) 2009-02-15

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00978215T ATE422494T1 (de) 1999-09-28 2000-09-26 Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung

Country Status (35)

Country Link
EP (1) EP1228063B1 (de)
JP (1) JP4919567B2 (de)
KR (3) KR100890473B1 (de)
CN (3) CN100422172C (de)
AR (3) AR025752A1 (de)
AT (1) ATE422494T1 (de)
AU (1) AU782820B2 (de)
BG (1) BG65860B1 (de)
BR (1) BRPI0014382B8 (de)
CA (1) CA2385817C (de)
CO (1) CO5200835A1 (de)
CZ (1) CZ304767B6 (de)
DE (1) DE60041548D1 (de)
DO (1) DOP2000000070A (de)
EE (1) EE05258B1 (de)
ES (1) ES2320525T3 (de)
GT (1) GT200000158A (de)
HR (1) HRP20020308A2 (de)
HU (1) HU230223B1 (de)
IL (3) IL148880A0 (de)
MA (1) MA25563A1 (de)
MX (1) MXPA02003156A (de)
MY (3) MY143377A (de)
NO (1) NO20021520L (de)
NZ (1) NZ518589A (de)
PA (1) PA8503201A1 (de)
PE (1) PE20010607A1 (de)
PL (1) PL205957B1 (de)
RS (1) RS50369B (de)
RU (1) RU2260008C2 (de)
SK (1) SK287417B6 (de)
TW (1) TW593315B (de)
UA (1) UA75053C2 (de)
WO (1) WO2001023375A2 (de)
ZA (1) ZA200202760B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416525A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
EP1415987B1 (de) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
US20050019424A1 (en) * 2001-12-21 2005-01-27 Adams Paul E. Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
EP1603566B1 (de) * 2003-03-11 2009-01-21 Novartis AG Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase
EP1616576A4 (de) * 2003-04-08 2010-02-10 Mitsubishi Tanabe Pharma Corp Spezifischer nad(p)h oxidase-hemmer
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
EP1797877A4 (de) 2004-09-13 2010-12-15 Eisai Co Ltd Gemeinsame verwendung einer verbindung auf sulfonamid-basis mit einem angiogenese-hemmer
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
EP1925676A4 (de) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Testverfahren für die wirkung eines vaskularisierungsinhibitors
WO2007118602A1 (en) * 2006-04-15 2007-10-25 Bayer Healthcare Ag Compounds for treating pulmonary hypertension
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
EP2119707B1 (de) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Zusammensetzung zur behandlung von nicht differenzierten formen von magenkrebsen
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
CN101481380B (zh) 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
EP2700403B1 (de) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutikum für tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
JP7624404B2 (ja) * 2019-04-22 2025-01-30 ミラティ セラピューティクス，インク． Ｐｒｃ２阻害剤としてのナフチリジン誘導体
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
CA2173493C (en) * 1994-08-09 2008-03-25 Nobuhisa Watanabe Fused pyridazine compounds
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP1107964B8 (de) * 1998-08-11 2010-04-07 Novartis AG Isochinoline derivate mit angiogenesis-hemmender wirkung
JP4673977B2 (ja) * 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf

Also Published As

Publication number Publication date
BR0014382B1 (pt) 2014-04-01
CN1769282A (zh) 2006-05-10
EP1228063A2 (de) 2002-08-07
SK5912002A3 (en) 2003-01-09
HU230223B1 (en) 2015-10-28
BG65860B1 (bg) 2010-03-31
IL193367A (en) 2011-03-31
MY143377A (en) 2011-05-13
CN100422172C (zh) 2008-10-01
KR20020038775A (ko) 2002-05-23
WO2001023375A2 (en) 2001-04-05
HRP20020308B1 (de) 2013-01-31
CO5200835A1 (es) 2002-09-27
KR100895572B1 (ko) 2009-04-29
JP2003526632A (ja) 2003-09-09
RU2260008C2 (ru) 2005-09-10
MY143580A (en) 2011-05-31
AR025752A1 (es) 2002-12-11
TW593315B (en) 2004-06-21
HUP0202704A2 (hu) 2002-12-28
EE200200161A (et) 2003-08-15
DOP2000000070A (es) 2002-02-28
IL193368A (en) 2011-05-31
PA8503201A1 (es) 2002-08-26
ZA200202760B (en) 2003-10-29
ES2320525T3 (es) 2009-05-25
HK1091818A1 (zh) 2007-01-26
CN100422173C (zh) 2008-10-01
AR082231A2 (es) 2012-11-21
NZ518589A (en) 2005-03-24
PL205957B1 (pl) 2010-06-30
AR082232A2 (es) 2012-11-21
PE20010607A1 (es) 2001-07-12
AU1569601A (en) 2001-04-30
NO20021520L (no) 2002-05-23
UA75053C2 (en) 2006-03-15
SK287417B6 (sk) 2010-09-07
BR0014382A (pt) 2003-06-24
CN1420879A (zh) 2003-05-28
BRPI0014382B8 (pt) 2021-05-25
PL366342A1 (en) 2005-01-24
AU782820B2 (en) 2005-09-01
EP1228063B1 (de) 2009-02-11
CN100374435C (zh) 2008-03-12
IL193367A0 (en) 2009-02-11
YU22902A (sh) 2004-12-31
CZ20021444A3 (cs) 2002-08-14
MXPA02003156A (es) 2002-09-30
RS50369B (sr) 2009-11-10
HRP20020308A2 (en) 2004-06-30
GT200000158A (es) 2002-03-16
WO2001023375A3 (en) 2002-05-02
HUP0202704A3 (en) 2003-12-29
EE05258B1 (et) 2010-02-15
CZ304767B6 (cs) 2014-10-08
CA2385817A1 (en) 2001-04-05
MY135058A (en) 2008-01-31
KR20080086547A (ko) 2008-09-25
KR20080091505A (ko) 2008-10-13
DE60041548D1 (de) 2009-03-26
JP4919567B2 (ja) 2012-04-18
CN1769283A (zh) 2006-05-10
IL148880A0 (en) 2002-09-12
CA2385817C (en) 2010-05-04
KR100890473B1 (ko) 2009-03-26
IL193368A0 (en) 2009-02-11
NO20021520D0 (no) 2002-03-26
MA25563A1 (fr) 2002-10-01
HK1091819A1 (zh) 2007-01-26
KR100895571B1 (ko) 2009-04-29
BG106637A (bg) 2003-02-28

Similar Documents

Publication Publication Date Title
DE60041548D1 (de) Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung
DE69923869D1 (de) Substituierte pyridine mit herbizider wirkung
DE69826841D1 (de) Phthalazines mit angiogenesis-hemmender wirkung
ATE330953T1 (de) Substituirte pyridine mit herbizider wirkung
ATE194832T1 (de) 2-aryl-substituierte pyridine
IS6518A (is) Pyridín, pyrimidín, pyrazín og tríazín setin með arýl og notkun þeirra
ATE249437T1 (de) Substituierte pyridine als selektive cyclooxygenase inhibitoren
ATE381556T1 (de) Pyridin-derivate mit ikb-kinase (ikk-beta) hemmender wirkung
DE60302336D1 (de) Neue pyridin- und quinolin-derivate
DE59710981D1 (de) Heterocyclisch kondensierte Pyridine als CETP Inhibitoren
ATE341546T1 (de) 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine
NO995340D0 (no) Ukonsolidert soneisolasjon og styring
HUP0101099A3 (en) Substituted pyridine and pyridazine compounds and their pharmaceutical use
NO984418D0 (no) Arylaminokondenserte pyridiner og pyrimidiner
DK1326841T3 (da) Pyridinon-derivater til behandling af atherosklerose
ATE265448T1 (de) Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung
DE10163359B4 (de) Pyridinderivat und dessen Komplex
DE69837621D1 (de) Substituierte pyrimidine und pyridine als unkrautbekämpfungsmittel
DE69627062D1 (de) Herbizide 2,6-disubstituierte Pyridine und 2,4-disubstituierte Pyrimidine
DE59102729D1 (de) Substituierte Pyridine.
DK1068194T3 (da) PDE IV-hæmmende pyridinderivater
DK1380297T3 (da) Orale sammensætninger med 8-chlor-6,11-dihydro-11(4-piperidyliden)-5H-benzo[5,6]-cyklo-hepta[1,2-b]pyridin
PT1149096E (pt) N-oxidos de piridina triciclicos agonistas de vasopressina
ATE271554T1 (de) Phenyl- und pyridyl-tetrahydro-pyridine mit tnf inhibitorischer wirkung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties